First Pharma to Restore Sense of Smell? Inside the FLAVOR Trial Quest to Treat Postviral Olfactory Loss
In this interview, I’m talking with Rick Geoffrion, Founder, President, and CEO of Cyrano Therapeutics, about FLAVOR, a Phase...
“Minutes, Not Days”: Site-Centric AI and Clinical Trial Experience
The coordinator stared at a 400-page EHR export, convinced the week was lost—until an AI pre-screen flagged 23 likely-eligible...
How Small Biotechs Navigate Clinical Trial Vendor Oversight
At SCOPE Europe 2025, a panel on vendor identification, selection, and management highlighted a pragmatic blueprint for small biopharma:...
Shining Light on Women’s Health: A New Non-Drug Vaginal Therapy
In this interview, I spoke with Dr. Melanie Santos, Chief Medical Officer at Cern Corporation, about a novel low...
New Analysis Supports Genetic Tool for Depression Treatment
In a retrospective re-analysis of Sanofi’s prior Phase 2 Major Depressive Disorder study (NCT00358631), patients receiving the vasopressin V1b...
Cidara Presents Late-Breaking Phase 2 CD388 Clinical Data
Cidara will deliver late-breaking Phase 2 data for its long-acting influenza prophylactic CD388 at ID Week on October 20,...
4DMT’s CF Drug Advances to Phase 2 with Foundation Support
Enrollment is underway in the Phase 2 stage of 4D Molecular Therapeutics’ AEROW trial with 2.5E14 vg set as...
Hutchmed to Present FRUSICA-2 Trial Data at ESMO Congress
Topline: In the Phase III FRUSICA-2 study (n=234) in second-line advanced renal cell carcinoma, fruquintinib plus sintilimab achieved a...
AdvanCell’s New Alpha Therapy Shows Promise for Prostate Cancer
AdvanCell’s ESMO abstract reports favorable safety and early anti-tumor activity for ADVC001, a Lead-212 (212Pb)-labeled PSMA radioligand, across seven...
The Human Cost of Fragmented Technology: A Conversation with Veeva’s Bree Burks
At the Veeva R&D and Quality Summit in Boston, we spoke with Bree Burks, Vice President of Strategy at...